Healthcare -
Medical - Diagnostics & Research - NASDAQ - US
$ 0.2198
15.7 %
$ 12.5 M
Market Cap
None
P/E
1. INTRINSIC VALUE
Balance Sheet
bioAffinity Technologies, Inc.
| Current Assets | 2.7 M |
| Cash & Short-Term Investments | 1.11 M |
| Receivables | 1.14 M |
| Other Current Assets | 451 K |
| Non-Current Assets | 3.82 M |
| Long-Term Investments | 0 |
| PP&E | 1.62 M |
| Other Non-Current Assets | 2.2 M |
| Current Liabilities | 3.1 M |
| Accounts Payable | 987 K |
| Short-Term Debt | 694 K |
| Other Current Liabilities | 1.42 M |
| Non-Current Liabilities | 807 K |
| Long-Term Debt | 807 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
bioAffinity Technologies, Inc.
| Revenue | 9.36 M |
| Cost Of Revenue | 0 |
| Gross Profit | 9.36 M |
| Operating Expenses | -74.7 K |
| Operating Income | -8.95 M |
| Other Expenses | 86.4 K |
| Net Income | -9.04 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
bioAffinity Technologies, Inc.
| Net Income | -9.04 M |
| Depreciation & Amortization | 606 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 0 |
| Change in Working Capital | 0 |
| Others | -7.26 M |
| Free Cash Flow | -7.26 M |
Wall Street Analysts Price Targets
bioAffinity Technologies, Inc.
BIAFW has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
BIAFW does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
bioAffinity Technologies, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
8. Profile
Summary
bioAffinity Technologies, Inc. BIAFW
COUNTRY
US
INDUSTRY
Medical - Diagnostics & Research
MARKET CAP
$ 12.5 M
Dividend Yield
0.00%
Description
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.
Contact
DE,
http://www.bioaffinitytech.com
IPO
Date
None
Employees
75
Officers
Ms. Julie Anne Overton
Director of Communications
Dr. William Bauta Ph.D.
Chief Science Officer
Mr. Xavier T. Reveles M.S.
Chief Operating Officer
Mr. Steven Girgenti
Founder & Executive Chairman of the Board
Mr. Dallas J. Coleman
Vice President of sales
Ms. Maria Zannes J.D.
Founder, President, Chief Executive Officer & Director
Mr. J. Michael Edwards CPA, M.B.A.
Chief Financial Officer & Principal Accounting Officer
Mr. Timothy P. Zannes J.D.
Executive Vice President, Secretary & General Counsel